QSP Model of Rheumatoid Arthritis
Development of mPBPK-target engagement model
A Bootstrapping Method to Optimize
Supporting dose decisions for Antibody Drug Conjugates
Does Progressive Disease Justify Pembrolizumab discontinuation
Extending a QSP model of T-Cell Dependent Bispecific Antibodies
Development of a mechanistic mPBPK_QSP
Evaluating the efficacy of combination of checkpoint inhibitors and chemotherapy in lung cancer using mechanistic model
Optimizing Lipid Nano-Particle(LNP) design for mRNA drug delivery, efficacy and dose prediction using mechanistic modeling
Development of a QSP model for prediction of mineral corticoid receptor antagonists-induced hyperkalemia
